OPKO Health, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US68375N1037
USD
1.35
0.02 (1.5%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About OPKO Health, Inc. stock-summary
stock-summary
OPKO Health, Inc.
Pharmaceuticals & Biotechnology
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
Company Coordinates stock-summary
Company Details
4400 Biscayne Blvd , MIAMI FL : 33137
stock-summary
Tel: 1 305 57541811 310 6917100
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 41 Schemes (11.07%)

Foreign Institutions

Held by 101 Foreign Institutions (4.25%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Phillip Frost
Chairman of the Board, Chief Executive Officer
Dr. Jane Hsiao
Vice Chairman of the Board, Chief Technical Officer
Dr. Jon Cohen
Director, Executive Chairman of BioReference Laboratories
Mr. Steven Rubin
Executive Vice President - Administration, Director
Dr. Robert Fishel
Independent Director
Dr. Anthony Japour
Independent Director
Dr. Richard Krasno
Independent Director
Dr. Richard Lerner
Independent Director
Dr. Roger Medel
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
157 Million
(Quarterly Results - Jun 2025)
Net Profit:
-148 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,169 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.06

stock-summary
Return on Equity

-14.14%

stock-summary
Price to Book

0.90